Toward the computer-aided discovery of FabH inhibitors. Do predictive QSAR models ensure high quality virtual screening performance?
暂无分享,去创建一个
Maykel Cruz-Monteagudo | Ann Nowé | Yunierkis Pérez-Castillo | Cosmin Lazar | Jonatan Taminau | Miguel Ángel Cabrera-Pérez | Mathy Froeyen
[1] J. Irwin,et al. Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.
[2] Hong-Jia Zhang,et al. Design, synthesis and biological evaluation of urea derivatives from o-hydroxybenzylamines and phenylisocyanate as potential FabH inhibitors. , 2011, Bioorganic & medicinal chemistry.
[3] Julie Clark,et al. Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening , 2013, J. Chem. Inf. Model..
[4] Yin Luo,et al. Synthesis of C(7) modified chrysin derivatives designing to inhibit beta-ketoacyl-acyl carrier protein synthase III (FabH) as antibiotics. , 2009, Bioorganic & medicinal chemistry.
[5] Simona Distinto,et al. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes? , 2008, J. Comput. Aided Mol. Des..
[6] R. Heath,et al. Roles of the FabA and FabZ β-Hydroxyacyl-Acyl Carrier Protein Dehydratases in Escherichia coli Fatty Acid Biosynthesis* , 1996, The Journal of Biological Chemistry.
[7] A. Yan,et al. Classification of Plasmodium falciparum glucose-6-phosphate dehydrogenase inhibitors by support vector machine , 2013, Molecular Diversity.
[8] Alexander Tropsha,et al. Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.
[9] H. Nikaido. Multidrug resistance in bacteria. , 2009, Annual review of biochemistry.
[10] Jin Chen,et al. Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[11] H. Yoneyama,et al. Antibiotic Resistance in Bacteria and Its Future for Novel Antibiotic Development , 2006, Bioscience, biotechnology, and biochemistry.
[12] R. Heath,et al. Fatty acid biosynthesis as a target for novel antibacterials. , 2004, Current opinion in investigational drugs.
[13] A. Sarai,et al. Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM) , 2011, Molecular Diversity.
[14] Xiao-Ming Wang,et al. Synthesis, antibacterial activities and molecular docking studies of Schiff bases derived from N-(2/4-benzaldehyde-amino) phenyl-N'-phenyl-thiourea. , 2011, Bioorganic & medicinal chemistry.
[15] Y. Castillo,et al. Bacterial beta-ketoacyl-acyl carrier protein synthase III (FabH): an attractive target for the design of new broad-spectrum antimicrobial agents. , 2008, Mini reviews in medicinal chemistry.
[16] R. Heath,et al. Regulation of Fatty Acid Elongation and Initiation by Acyl-Acyl Carrier Protein in Escherichia coli(*) , 1996, The Journal of Biological Chemistry.
[17] K. Niihara,et al. Synthesis of C , 2013 .
[18] Alexander Golbraikh,et al. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection , 2004, Molecular Diversity.
[19] Shuai Zhang,et al. Design, synthesis and antimicrobial activities of nitroimidazole derivatives containing 1,3,4-oxadiazole scaffold as FabH inhibitors. , 2012, Bioorganic & medicinal chemistry.
[20] Nina Nikolova-Jeliazkova,et al. QSAR Applicability Domain Estimation by Projection of the Training Set in Descriptor Space: A Review , 2005, Alternatives to laboratory animals : ATLA.
[21] Xiayang Qiu,et al. First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. , 2003, Journal of medicinal chemistry.
[22] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[23] S. Chirala,et al. Human fatty acid synthase: properties and molecular cloning. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] Christopher I. Bayly,et al. Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..
[25] H Matter,et al. Random or rational design? Evaluation of diverse compound subsets from chemical structure databases. , 1998, Journal of medicinal chemistry.
[26] Ann Nowé,et al. GA(M)E-QSAR: A Novel, Fully Automatic Genetic-Algorithm-(Meta)-Ensembles Approach for Binary Classification in Ligand-Based Drug Design , 2012, J. Chem. Inf. Model..
[27] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[28] K. Reynolds,et al. 1,2-Dithiole-3-Ones as Potent Inhibitors of the Bacterial 3-Ketoacyl Acyl Carrier Protein Synthase III (FabH) , 2004, Antimicrobial Agents and Chemotherapy.
[29] Yin Luo,et al. Design and synthesis of novel deoxybenzoin derivatives as FabH inhibitors and anti-inflammatory agents. , 2010, Bioorganic & medicinal chemistry letters.
[30] Hong-Jia Zhang,et al. Synthesis, molecular modeling and biological evaluation of β-ketoacyl-acyl carrier protein synthase III (FabH) as novel antibacterial agents. , 2011, Bioorganic & medicinal chemistry.
[31] Richard W. Hamming,et al. Error detecting and error correcting codes , 1950 .
[32] Christopher T. Walsh,et al. Antibiotics for Emerging Pathogens , 2009, Science.
[33] Fernanda Borges,et al. Combining QSAR classification models for predictive modeling of human monoamine oxidase inhibitors. , 2013, European journal of medicinal chemistry.
[34] I. Tetko,et al. ISIDA - Platform for Virtual Screening Based on Fragment and Pharmacophoric Descriptors , 2008 .
[35] Ann Nowé,et al. Molecular dynamics and docking simulations as a proof of high flexibility in E. coli FabH and its relevance for accurate inhibitor modeling , 2011, J. Comput. Aided Mol. Des..
[36] S. Cho,et al. HQSAR study of β-ketoacyl‐acyl carrier protein synthase III (FabH) inhibitors , 2007 .
[37] R. Monaghan,et al. Antibacterial drug discovery--then, now and the genomics future. , 2006, Biochemical pharmacology.
[38] Yin Luo,et al. Design, synthesis, and structure-activity relationships of pyrazole derivatives as potential FabH inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[39] Thomas J. Crisman,et al. Which aspects of HTS are empirically correlated with downstream success? , 2008, Current opinion in drug discovery & development.
[40] Kui Cheng,et al. Design and synthesis of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III (FabH) as potential antibacterial agents. , 2010, European journal of medicinal chemistry.
[41] D. Moir,et al. New classes of antibiotics. , 2012, Current opinion in pharmacology.
[42] Andreas Bender,et al. Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..
[43] N. Waters,et al. Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[44] K. Gajiwala,et al. Structure-based design, synthesis, and study of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents , 2005 .
[45] Yan-Bin Zhang,et al. Discovery and modification of sulfur-containing heterocyclic pyrazoline derivatives as potential novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors. , 2012, Bioorganic & medicinal chemistry letters.
[46] Y. S. Prabhakar,et al. QSAR studies on benzoylaminobenzoic acid derivatives as inhibitors of beta-ketoacyl-acyl carrier protein synthase III. , 2008, European journal of medicinal chemistry.